All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How should molecular profiling be used to guide MDS therapy?
Bookmark this article
During the Acute Leukemia Forum (ALF) 2021, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, How should molecular profiling be used to guide MDS therapy?
How should molecular profiling be used to guide MDS therapy?
It is well understood that MDS is caused by somatic mutations in blood cells, influencing a patient's clinical presentation. In this video, Bejar discusses how DNA sequencing can help determine the diagnosis, prognosis, and identify targeted therapy options for patients with a wide variety of MDS risk features and gene mutations.
More about...
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox